IDEAYA Biosciences Reports $207.8M Collaboration Revenue and $119.2M Net Income for Q3 2025

IDEAYA Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company achieved collaboration revenue of $207.8 million, a notable increase from zero revenue in the same period last year. This revenue was primarily attributed to the Servier License Agreement, which included an upfront payment of $210 million. The net income for the quarter was $119.2 million, a substantial turnaround from a net loss of $51.8 million in the prior year, reflecting a 254% increase in profitability.

In terms of operational expenses, IDEAYA Biosciences saw a rise in total operating expenses to $99.4 million for the quarter, up from $66.9 million a year earlier. Research and development expenses increased by 45% to $83.0 million, driven by costs associated with advancing clinical trials for its lead product candidates. General and administrative expenses also rose by 68% to $16.4 million, reflecting increased personnel costs and consulting fees. Despite these increases, the company reported a significant reduction in its loss from operations, which decreased by 65% to $64.7 million for the nine-month period ending September 30, 2025.

The company’s balance sheet showed total assets of approximately $1.19 billion, up from $1.12 billion at the end of 2024. Cash and cash equivalents increased significantly to $298.9 million, compared to $84.4 million at the end of the previous fiscal year. This increase in liquidity is attributed to successful capital raises, including an at-the-market offering program that generated $25 million in net proceeds during the nine months ended September 30, 2025. The company’s accumulated deficit stood at $653.3 million, reflecting its ongoing investment in research and development.

Strategically, IDEAYA has made significant strides in its clinical pipeline, which includes seven potential first-in-class product candidates. The company is advancing its lead candidate, darovasertib, in multiple clinical trials, including a Phase 2/3 trial in combination with crizotinib for metastatic uveal melanoma. Additionally, IDEAYA entered into a licensing agreement with Servier for darovasertib, which is expected to enhance its market presence outside the United States. The company also reported progress in its collaborations with GSK and Gilead, further solidifying its operational framework.

Looking ahead, IDEAYA anticipates continued investment in its clinical programs, with expectations of increased operating expenses as it advances its product candidates through clinical trials. The company believes its current cash reserves will be sufficient to fund operations for at least the next 12 months. However, IDEAYA acknowledges the inherent risks in biotechnology development, including the need for additional financing to support its growth and the potential for delays in clinical trials or regulatory approvals.